Synthonics, Inc., a specialty pharmaceutical company focused on the development of proprietary metal coordinated pharmaceuticals, announced today the approval of the Phase 1 clinical trial of PolyZincLiothyronine (PZL), a novel extended release Liothyronine (LT3) compound for the management of hypothyroidism. Enrollment of healthy volunteers is now underway following authorization of the study by the FDA and the University of Chicago’s Institutional … Read More